Alumis Inc. Common Stock (ALMS)

About ALMS

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory a…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

237

Website

www.alumis.com/

Fundamentals

1-day range

$22.35$23.28

Market cap

$3.33B

P/E (trailing)

—

P/E (forward)

-7.81

EPS (trailing)

$-1.93

Dividend yield

—

Beta

0.72

Avg. volume

1.30M

Forecasts

9 analyst ratings

Alumis Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ALMS

  Alumis Inc. Common Stock

  $22.38

  ▼ 3.58%
  Market cap $3.33BP/E —
  $3.76$31.35
• TLX

  Telix Pharmaceuticals Limited American Depositary Shares

  $11.28

  ▼ 0.84%
  Market cap $3.39BP/E —
  $6.28$12.5
• ARQT

  Arcutis Biotherapeutics Inc. Common Stock

  $23.78

  ▼ 4.38%
  Market cap $3.24BP/E 113.86
  $15.1$31.77
• GPCR

  Structure Therapeutics Inc. American Depositary Shares

  $47.38

  ▼ 3.74%
  Market cap $3.44BP/E —
  $18.26$94.9
• NAMS

  NewAmsterdam Pharma Company N.V. Ordinary Shares

  $25.9

  ▼ 3.32%
  Market cap $3.21BP/E —
  $23.05$42.21
• ELVN

  Enliven Therapeutics Inc. Common Stock

  $57.82

  ▼ 4.43%
  Market cap $3.53BP/E —
  $14.79$62.32
• MBX

  MBX Biosciences Inc. Common Stock

  $63.04

  ▼ 5.05%
  Market cap $3.07BP/E —
  $9.63$72.64

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target
  benzinga · 8/14/2026
• HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target
  Benzinga · 8/14/2026
• Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
  Yahoo · 8/13/2026
• Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate
  Benzinga · 8/13/2026
• 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
  Yahoo · 8/11/2026
• Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
  Benzinga · 8/11/2026
• Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
  Yahoo · 8/10/2026
• Alumis Reports Topline Results From Ongoing ONWARD3 Long-Term Extension Study Showing 54% Of Patients Reached Complete Skin Clearance After 48 Weeks Of Continuous Envudeucitinib Treatment
  Benzinga · 8/10/2026

• Sanam Pangali · August 3, 2026 · Sale

  1.4K @ $26.37
• Mark Christopher Bradley · August 3, 2026 · Sale

  2.6K @ $26.37
• Jorn Drappa · August 3, 2026 · Sale

  2.4K @ $26.37
• David M. Goldstein · August 3, 2026 · Sale

  2.6K @ $26.37
• John R. Schroer · August 3, 2026 · Sale

  3.3K @ $26.37
• Roy C. Hardiman · August 3, 2026 · Sale

  2.7K @ $26.37
• Sanam Pangali · July 6, 2026 · Option Exercise

  5.0K @ $5.06
• Sanam Pangali · July 6, 2026 · Sale

  5.0K @ $28
• Lynn A. Tetrault · June 30, 2026 · Grant

  15.5K
• Lynn A. Tetrault · June 30, 2026 · Grant

  3.6K
• Sapna Srivastava · June 30, 2026 · Grant

  15.5K
• Sapna Srivastava · June 30, 2026 · Grant

  3.6K
• Zhengbin Yao · June 30, 2026 · Grant

  15.5K
• Zhengbin Yao · June 30, 2026 · Grant

  3.6K
• Patrick Machado · June 30, 2026 · Grant

  15.5K

Institutional Ownership

March 31, 2026

Total shares held

98.24M

Total value held

$2.09B

Institutional holders

192